Daniel Tawfik: Rapamycin, Metformin, and Fisetin for Longevity

Cellular senescence serves as a fundamental driver of age-related decline, occurring when damaged cells enter a persistent, non-proliferating state that secretes harmful inflammatory molecules known as the Senescent Associated Secretory Phenotype (SASP). While this mechanism initially protects against tumor genesis, its accumulation over time causes systemic tissue dysfunction. Pharmacological interventions like Metformin and Rapamycin function as mTOR inhibitors, effectively mimicking fasting states to induce autophagy and suppress this deleterious hyper-functionality. Complementing these, senolytics such as Fisetin actively target and eradicate existing senescent cells. Daniel Tawfik, founder of HealthSpan, bridges the gap between longevity research and clinical practice by providing a telemedicine-based, physician-supervised framework for healthy individuals to access these interventions. This approach shifts the focus from treating acute age-related diseases to proactively managing the underlying cellular mechanisms that dictate human healthspan.